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Genomic analysis of a metronidazole resistant H. bizzozeronii strain revealed a frame length extension of the
oxygen-insensitive NAD(P)H-nitroreductase HBZC1_00960 (RdxA), associated with the disruption of the C-terminal
cysteine-containing conserved region (IACLXALGK). This was the result of the extension (from C8 to C9) of a simple
sequence cytosine repeat (SSCR) located in the 3’ of the gene. A 3' SSCR is also present in the rdxA homolog of H.
heilmannii sensu stricto, but not in H. pylori. We showed that in the majority of in vitro spontaneous H. bizzozeronii
metronidazole resistant mutants, the extension of the 3′ SSCR of rdxA was the only mutation observed. In addition,
we observed that H. bizzozeronii ΔrdxA mutant strain showed the same MIC value of metronidazole observed in the
spontaneous mutants. These data indicate that loss of function mutations in rdxA and in particular the disruption of
the conserved region IACLXALGK is associated with reduced susceptibility to metronidazole in H. bizzozeronii.
Slipped-strand mispairing of the SSCR located in the 3′ of the H. bizzozeronii rdxA appears to be the main
mechanism. We also observed that H. bizzozeronii acquires resistance to metronidazole at high mutation rate, and
that serial passages in vitro without selection induced an increased level of susceptibility. In conclusion, contrary to
what was previously described in H. pylori, the H. bizzozeronii rdxA appears to be a contingency gene which
undergoes phase variation. The contingency nature of rdxA should be carefully considered when metronidazole is
used in the treatment of H. heilmannii-associated gastritis.Introduction
The human-adapted pathogen Helicobacter pylori is one
of the most common causes of bacterial infections
worldwide, and it is recognized as an etiologic agent of
chronic gastritis, peptic ulcers, gastric adenocarcinoma
and MALT lymphoma [1]. Humans can also be sporad-
ically infected by non-H. pylori gastric Helicobacter spe-
cies, referred to as H. heilmannii sensu lato, that are also
able to cause gastritis [2]. H. heilmannii s.l. comprises
very fastidious zoonotic Helicobacter species, including
H. bizzozeronii, H. felis, H. suis and H. heilmannii sensu
stricto, which are all known to colonize the gastric
mucosa of different animal species [2]. Although the* Correspondence: mirko.rossi@helsinki.fi
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reproduction in any medium, provided the orabsence of a simple laboratory test have lead to an
underestimation of the infection rate, H. heilmannii s.l.
is consider to be a rare type of zoonosis, with prevalence
ranging between 0.2% and 6.5% depending of the geo-
graphic region [2-5]. Due to the rarity of these infections
and the peculiar growth requirements of H. heilmannii s.l.,
which limits the isolation of pure cultures [2], very little
is known about the prevalence of antibiotic resistance
in these species [6-9]. Therefore, the optimal treatment
regimen for these infections remains unclear, and con-
ventional H. pylori eradication treatment is generally
recommended [10,11]. The standard treatment for
H. pylori appears to eradicate H. heilmannii s.l. infec-
tion in most patients [3,5,10-13]. However, cases of
failed treatment have been reported [7,14]. The peculiarl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the application of molecular tools, affecting studies on
the molecular mechanisms of antibiotic resistance in
these species and hampering the adoption of new, spe-
cific strategies to treat patients after a failed treatment.
To better understand the molecular mechanisms of
antibiotic resistance in H. heilmannii s.l., we investi-
gated the potential reasons behind the failed treatment
of a H. bizzozeronii infection in a 47 year-old woman
suffering with chronic gastritis [7]. A few months after
the diagnosis of H. bizzozeronii-associated gastritis,
the patient was treated with a seven-day course of
lansoprazole 30 mg twice daily, tetracycline 500 mg
four times daily and metronidazole 400 mg three times
daily. After the treatment, the patient’s symptoms be-
came less severe and the patient started to gain weight.
However, she continued to suffer from mild nausea
associated with eating warm foods, and, after a few
months, H. bizzozeronii was re-isolated from antrum
samples obtained in a follow-up endoscopy [7]. The
H. bizzozeronii obtained before the treatment was re-
sistant to tetracycline, but a heterogeneous resistance
profile for metronidazole was observed [15]. In fact,
H. bizzozeronii CIII-1ORG (an isolate obtained from the
corpus of the patient‘s stomach before the treatment)
showed an MIC of metronidazole equal to 32 μg/mL,
but the MIC value for its derived clone CIII-1GEN,
obtained by amplification of a single colony, was 4 μg/
mL. These data indicated the simultaneous presence of
metronidazole susceptible and resistant H. bizzozeronii
variants before the treatment [15]. After treatment, the
isolated H. bizzozeronii (antrum T1) was resistant to
both drugs [15]. Metronidazole is considered a pro-
drug whose activation requires intracellular reduction
by anaerobic or microaerobic microorganisms; this
results in the production of bactericidal cytotoxic radi-
cals [16,17]. In H. pylori the main causes of metro-
nidazole resistance are mutations inactivating two
nitroreducate genes: rdxA and frxA [16,17]. However
conflicting evidence correlating the oxygen-insensitive
nitroreductase RdxA and/or the NAD(P)H flavin oxi-
doreductase FrxA with the resistant phenotype,
indicate that the molecular basis of resistance in this
species remains unclear [16,17].
A comparative genomic analysis of the H. bizzozeronii
isolates obtained before and after the treatment showed
that, among the five putative nitroreductases identified in
the genome of H. bizzozeronii CIII-1GEN, only the oxygen-
insensitive NAD(P)H-nitroreductase HBZC1_00960, show-
ing 47% identity with H. pylori RdxA HP0954, was
affected [15].
This study investigates the role of HBZC1_00960
(H. bizzozeronii RdxA homolog) in the molecular mech-
anisms of metronidazole resistance in H. bizzozeronii.Materials and methods
Bacterial strains, growth conditions, DNA manipulations
and PCR
For this study, the human-derived H. bizzozeronii strain
CIII-1GEN, which exhibited a metronidazole MIC of
4 μg/mL, was selected [7,15]. In addition, the canine-
derived H. bizzozeronii CCUG 35545T strain (MIC =
8 μg/mL) [18] was used for the mutation analysis.
Helicobacter spp. strains were cultured on HP agar
plates (LabM Limited, Lancashire, UK) as previously
described [19]. For electroporation, H. bizzozeronii
strains were cultivated in liquid media constituted by
Brain Heart Infusion (BHI, BD, Becton, Dickinson and
Co., NJ, USA) containing 10% Fetal Bovine Serum
(Gibco®, Invitrogen Carlsbad, CA, USA), Skirrow select-
ive supplement (Oxoid Ltd., Cambridge, UK) and Vitox
supplement (Oxoid) (BHI-FBv) at 37°C in a jar with
microaerobic atmosphere supplemented with hydrogen.
The E. coli TOPO10 strain (Invitrogen Corporation,
Carlsbad, CA, USA) was cultivated on Luria-Bertani
(LB) agar or broth supplemented with 100 μg/mL ampi-
cillin or 10 μg/mL chloramphenicol when needed. The
H. bizzozeronii genomic DNA was prepared as previ-
ously described [20]. PCRs were performed in 25 μL re-
actions using Phusion® High-Fidelity DNA Polymerase
(Finnzymes, Oy, Espoo, Finland) and 25 pmol of primers
(Table 1).
Antimicrobial susceptibility of H. bizzozeronii
The minimum inhibitory concentration (MIC) value of
metronidazole (Sigma-Aldrich) was estimated using the
agar dilution method. Briefly, HP agar plates supplemented
with serial dilutions of the antibiotics were inoculated
with 10 μL bacterial inoculums (corresponding to
approximately 103 cfu). The inoculum was prepared by
diluting (1:10) a 0.6-0.8 OD600 bacterial suspension
obtained from 4 days’ culture on HP agar plates. The
plates were incubated at 37°C in the microaerobic in-
cubator. The MIC values were determined by three in-
dependent assays after 4 and 6 days of incubation.
H. bizzozeronii CIII-1GEN (MIC = 4 μg/mL) was used as
reference control [15]. The EUCAST 2012 clinical
breakpoint of metronidazole (> 8 μg/mL) described for
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resistant or susceptible [21].
Selection of spontaneous metronidazole-resistant H.
bizzozeronii isogenic mutants
Spontaneous metronidazole-resistant H. bizzozeronii mu-
tants were selected by a single passage in media containing
four times the MIC of metronidazole. Briefly, a suspension
containing approximately 106 cfu/mL of 3-day-grown
H. bizzozeronii CIII-1GEN was prepared in BHI-Fbv and
cultured in biphasic medium (HP coupled with BHI-Fbv)
for 36 h. Then, 100 μL was spread onto HP agar plates
containing 16 μg/mL of metronidazole. After six to ten
days of incubation, resistant colonies were picked up and
transferred to a new HP plate containing 16 μg/mL of
metronidazole before being frozen at −70°C in 10% gly-
cerol for further use. From each mutant, HBZC1_00960
was amplified and sequenced. The experiment was re-
peated three times.
Construction of H. bizzozeronii rdxA::cat (ΔrdxA) isogenic
mutants
Chromosomal inactivation of the HBZC1_00960 gene
(H. bizzozeronii rdxA homolog) was performed by allelic
exchange using the chloramphenicol resistance gene
(cat), as previously described [22]. The cat gene was in-
troduced in the same direction as the target gene using
XbaI and KpnI restriction sites. The resultant plasmid,
pCP5, was constructed and amplified in E. coli TOPO10
and used as a suicide plasmid in H. bizzozeronii. Mutants
were obtained by electroporation as described for H. felis
[23]. After electroporation, the bacteria were left to
recover on HP agar plates for 48 h under microaerobic
conditions. The mutant strains (H. bizzozeronii rdxA::cat)
were selected on HP agar plates supplemented with
chloramphenicol (10 mg/mL). The plates were incu-
bated up to 10 days, and the site of recombination was
verified by PCR.
Determination of mutation rate and mutation frequency
by Luria-Delbrück fluctuation analysis
The mutation rate and frequency of H. bizzozeronii for
metronidazole were calculated using Luria-Delbrück
fluctuation analysis [24]. Briefly, from a three days’ cul-
ture, a suspension of approximately 106H. bizzozeronii
CIII-1GEN per mL was prepared in BHI-Fbv broth and
divided into twenty-four 0.5 mL aliquots. These aliquots
were allowed to grow in biphasic medium (HP coupled
with BHI-Fbv) for 36 h to obtain parallel, independent
cultures. The number of resistant mutants that emerged
in each culture was determined by plating an aliquot of
the culture on HP agar plates containing 16 μg/mL
metronidazole. The total number of cells (Nt) was deter-
mined by plating an appropriate dilution of threecultures on non-selective medium. Colonies on both
selective and non-selective plates were counted after a
maximum of 10 days of incubation. The frequency of
resistant mutants was expressed as the mean number of
resistant cells divided by the total number of viable cells
per culture. For the calculation of the mutation rate, the
most likely number of mutations per culture observed
(mobs) was first calculated from the distribution of num-
bers of resistant mutants in the independent cultures by
the Ma-Sandri-Sarkar maximum-likelihood method [24]
using the FALCOR web tool [25]. The effect of the
sampling in the calculation of the most likely number of
mutations was corrected for by applying the following
equation: mact ¼ mobs z−1ð Þz lnz ; where z is the fraction of cul-
ture plated. Then, the mutation rate (μ) per cell division
was calculated as: μ ¼ mactNt , where Nt is the total cell
number per culture [24].
Time-kill curve for metronidazole
H. bizzozeronii strain CIII-1GEN and its derivate CIII-1GEN
ΔrdxA and CIII-1GEN M11 (spontaneous metronidazole
resistant mutant) were sequentially sub-cultivated.
CIII-1GEN was maintained on non-selective plates,
CIII-1GEN rdxA::cat was maintained in the presence of
16 μg/mL of metronidazole, and CIII-1GEN M11 was
maintained in both conditions. After 10, 12 and 15 pas-
sages, approximately 108 cells/mL of each H. bizzozeronii
strain were suspended in BHI-Fbv with or without 32 μg/
mL of metronidazole. After 16 h, the intracellular ATP
levels were measured using BacTiter-GloTM (Promega).
The experiment was performed in duplicate. The data
were analyzed as percentage of relative light units (RLU)
of the treated samples compared to the untreated ones.
The statistical analysis was performed by applying One-
way ANOVA analysis of variance followed by Tukey‘s
Multiple Comparison using GraphPad Prism version 4.03
for Windows (GraphPad Software, San Diego, California,
USA).
Results
A multialignment of the C-terminal part of the amino
acid sequence of the RdxA homologs of H. bizzozeronii
CIII-1GEN (HBZC1_00960) and of several other Heli-
cobacter species with the predicted RdxA amino acid se-
quence of the resistant variant H. bizzozeronii Antrum
T1 [15] is shown in Figure 1. As compared to the iso-
genic strain CIII-1GEN, the resistant H. bizzozeronii vari-
ant Antrum T1 showed a frame length extension leading
to the disruption of the C-terminal cysteine-containing
conserved region IACLXALGK (amino acids from pos-
ition 182 to position 190 of HBZC1_00960) in the RdxA
homolog. The frame length extension was a result of the
insertion of a single cytosine in a homopolymeric run
Figure 1 Multialignment of the predicted amino acid sequences of RdxA C-termini from different Helicobacter spp. The area where the
simple sequence cysteine repeat is located in H. bizzozeronii is highlighted, and a multialignment of the corresponding nucleotide sequences is
shown. The C-terminal cysteine-containing conserved region is marked in bold. HBZ Antrum T1: H. bizzozeronii metronidazole resistant strain
(MIC 32 μg/mL); HBZ CIII-1GEN: H. bizzozeronii isogenic metronidazole susceptible strain (MIC 4 μg/mL); HFE CS1: H. felis CS1T (Hfelis_12350); HHE
ASB1.4: H. heilmannii sensu stricto ASB1.4 T (CCM10903); HCE MIT00-7128: H. cetorum MIT00-7128 (HCw_05595); HAY SHEEBA: H. acinonychis strain
Scheeba (Hac_1030); HPY Puno135: H. pylori Puno135 (HPPN135_04725); HPY 26695: H. pylori 26695 (HP0954); HPY B38: H. pylori B38
(HELPY_0940).
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codon 178 to codon 180 of HBZC1_00960). A 3' simple
sequence cytosine repeat (SSCR) was also present in the
same position in the rdxA of the H. heilmannii s.s. type
strain but not in other gastric Helicobacter species
(Figure 1). To verify whether the instability of the 3’ SSCR
of H. bizzozeronii rdxA was associated with metronidazole
resistance, the rdxA genes of 11 metronidazole-resistant
H. bizzozeronii CIII-1GEN isogenic spontaneous mutants
were sequenced. All of the isogenic mutants obtained
in three independent experiments showed a MIC of
32 μg/mL (eight-fold more than the MIC described for
the parental strain). In 10 out of 11 mutants, the extension
of the SSCR (C8 to C9) in position 178–180 was the only
modification observed in rdxA. However, the M9 mutant
contained a single base deletion upstream of the SSCR,
which induced the formation of a premature stop-codon
in RdxA, and extension of the SSCR was not observed
(Table 2).
To further explore the role of rdxA in H. bizzozeronii’s
resistance to metronidazole, the gene was inactivated
using a chloramphenicol cassette in two different strains:
CIII-1GEN and CCUG 35545T. Due to the lack of a suit-
able complementation protocol for H. bizzozeronii, two
independent mutants for each strain were selected as a
control for secondary mutations. All of the mutants
showed eight-fold increased MIC values for metronida-
zole when compared to the respective parental strain
(Table 2).The mutation rate for H. bizzozeronii CIII-1GEN gaining
metronidazole resistance was estimated by Luria-Delbrück
fluctuation analysis, and the results are presented in
Table 3. In the first experiment, the rate was calculated to
be 4.78 × 10-6. However, in all of the replicates of the sub-
sequent two experiments the number of mutant colonies
was above 300, hampering the estimation of the mutation
rate. Thus, in a fourth assay the fraction of plated volume
(z) was decreased to 0.02, allowing the determination of a
mutation rate of 1.74 × 10-5. The mutation frequencies
were estimated to be 4.96 × 10-5 and 2.38 × 10-4 in the first
and fourth experiments, respectively.
A luciferase-based bacterial cell viability assay was used
to determine the bactericidal effect of metronidazole on
H. bizzozeronii strain CIII-1GEN and its derivate CIII-1GEN
ΔrdxA and CIII-1GEN M11 after sequential subculture.
Time-kill curves were generated to measure the decrease
in intracellular ATP after treatment with 1× the MIC of
metronidazole (calculated for the mutant H. bizzozeronii
CIII-1GEN ΔrdxA). The results are shown in Figure 2,
where the data are plotted as a percentage of relative
light units (RLU) of the treated samples compared to
the untreated ones. In order to minimize the effect on
the phenotype of phase variation of loci other than
rdxA, CIII-1GEN M11, obtained by pooling several col-
onies of spontaneous mutants from different plates, was
selected. The extension of the SSCR (C8 to C9) in the
position 178–180 was the only modification observed in
rdxA of CIII-1GEN M11. After 16 h of exposure, the
Table 2 MIC values of metronidazole after 4 days of
incubation for H. bizzozeronii strain CIII-1GEN, H. bizzozeronii
CCUG 35545T, and corresponding mutants
H. bizzozeronii
strains





CIII-1GEN M1 C9 32
CIII-1GEN M2 C9 32
CIII-1GEN M3 C9 32
CIII-1GEN M4 C9 32
CIII-1GEN M5 C9 32
CIII-1GEN M6 C9 32
CIII-1GEN M7 C9 32
CIII-1GEN M8 C9 32
CIII-1GEN M9 C8 A188→. 32
CIII-1GEN M10 C9 32
CIII-1GEN M11 C9 32
CIII-1GEN C1 C8 rdxA::cat 32
CIII-1GEN C2 C8 rdxA::cat 32
CCUG 35545T NS* 8
CCUG 35545T S1 NS rdxA::cat 64
CCUG 35545T S2 NS rdxA::cat 64
The length of the 3′ SSCR and mutations in rdxA are indicated for each strain.
*NS: not sequenced.
Kondadi et al. Veterinary Research 2013, 44:56 Page 5 of 7
http://www.veterinaryresearch.org/content/44/1/56spontaneous metronidazole-resistant isogenic mutant
CIII-1GEN M11 maintained on non-selective plates
survived similarly to the wild type but significantly less
well than CIII-1GEN ΔrdxA. In contrast, when CIII-1GEN
M11 was maintained on selective plates, the percentage
of survival was not significantly different to any of the
other conditions tested. However, in the absence of
metronidazole, CIII-1GEN M11 survived less well than
the same strain maintained in medium containing the
antibiotic. Therefore, although no statistical significance
was found between the survival capability of CIII-1GEN
M11 when sub-cultivated with or without metronida-
zole, it tends to become more susceptible in the absence
of selection after a small number of in vitro passages.Table 3 Fluctuation analysis for the calculation of the mutatio
which becomes resistant to metronidazole








1 2.18 × 107 0.08 87
2 1.07 × 108 0.08 > 300
3 1.40 × 107 0.08 > 300
4 1.30 × 107 0.02 62
There are 21 independent cultures for each experiment.Discussion
In association with other antibiotics, metronidazole is
largely used in the first-line treatment of H. pylori infec-
tions [26], and an increased incidence of resistant strains
has been observed in the last few years [27], with current
rates varying from 17% in Europe to 44% in America
[28]. In contrast, almost no data are available concerning
metronidazole resistance in H. bizzozeronii and other
species of the H. heilmannii s.l. (such as H. salomonis
and H. felis) [8]. The MICs of metronidazole for six
H. bizzozeronii strains of animal origin have been esti-
mated (by the agar dilution method) to range from 1 to
8 μg/mL [8], suggesting that this antibiotic could be effi-
ciently applied to eradicate H. bizzozeronii infections.
However, the analysis of isolates obtained from multiple
biopsy samples from the same patient [7,15] revealed the
simultaneous presence of metronidazole-susceptible and
resistant variants [15]. These data suggest that the iso-
genic variation of H. bizzozeronii may lead to the accumu-
lation of heteroresistant phenotypes for metronidazole,
resulting in treatment failure [15].
Metronidazole resistance is a strong predictor of
treatment failure for Helicobacter infections when the
treatment contains metronidazole [26]. However, due to
insufficient information about the genetic background
of the resistant phenotype, non-invasive detection of
metronidazole resistance is not yet feasible [16,26]. Sev-
eral years of investigation have provided evidence that
the main causes of metronidazole resistance in H. pylori
are mutations that alter the correct function of the
nitroreductases rdxA or frxA [16]. However, this resist-
ance has recently been shown to involve more complex
changes than the simple inactivation of rdxA or frxA,
including intracellular redox potential [16] and global
gene regulation [29,30]. To investigate possible changes
in H. bizzozeronii after the acquisition of metronidazole
resistance, a comparative genome analysis of susceptible
and resistant isogenic strains has been performed [15].
Numerous single nucleotide polymorphisms (SNPs) and
insertions or deletions (Indels) were detected in the
metronidazole-resistant strain compared to the isogenic





22.872 104.44 4.78 × 10-6 4.96 × 10-5
ND ND ND ND
ND ND ND ND
18.099 226.70 1.74 × 10-5 2.38 × 10-4
Figure 2 Killing effect of metronidazole (MTZ) after 16 h of
exposure against H. bizzozeronii strains. The figure shows the
time-kill curve for H. bizzozeronii strains CIII-1GEN, its derivate CIII-1GEN
ΔrdxA and CIII-1GEN M11 maintained in the presence or absence of
MTZ (marked with MTZ in the figure). Data are plotted as the
percentage of intracellular ATP, shown as relative light units (RLU), of
the treated samples compared to the untreated ones. Means
statistically significant different from the wild type strain CIII-1GEN are
indicated with an asterisk, while means statistically significant
different from the mutant strain CIII-1GEN ΔrdxA are indicated with a
hash tag (Turkey’s HSD, ρ < 0.05).
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However, among the five nitroreductases identified in the
H. bizzozeronii CIII-1GEN genome [20], only the homolog
of H. pylori rdxA was affected in the resistant strain, and
its C-terminal cysteine-containing conserved region
(IACLXALGK) was disrupted [15]. This mutation resulted
from the extension (from C8 to C9) of a simple sequence
cytosine repeat (SSCR) located in the 3’ region of the gene.
A comparative analysis showed that a similar 3' SSCR is
also present in the same position in the rdxA homolog of
H. heilmannii s.s. but not in H. pylori. In this study, we
showed that the extension of the 3′ SSCR of rdxA was the
only mutation detected in the majority of in vitro spontan-
eous H. bizzozeronii metronidazole resistant mutants. In
addition, we observed that an H. bizzozeronii ΔrdxA mu-
tant strain showed the same MIC value of metronidazole
that was observed in the spontaneous mutants. These data
indicate that loss of function mutations in rdxA, and, in
particular, the disruption of the conserved region
IACLXALGK, are sufficient to produce clinically signifi-
cant resistance to metronidazole in H. bizzozeronii. These
findings extend our knowledge of the types of mutations
that affect the functionality of rdxA in Helicobacter spp.,
and they support the idea that the C-terminal cysteine-
containing conserved region plays a critical role in the
ability of RdxA to catalyze nitroreduction [31]. Moreover,
slipped-strand mispairing of the rdxA 3′SSCR appears to
be the most frequent mechanism leading to the inhibition
of the H. bizzozeronii metronidazole-nitroreductaseactivity. Therefore, H. bizzozeronii rdxA represents the
first example of a contingency gene being associated with
metronidazole resistance.
Simple sequence repeats in Helicobacter and other
bacterial genomes can mediate phase variation due to
their high mutation rates and reversible mutations, pro-
viding a population-based mechanism for stochastic
variation in expression of specific genes and rapid adap-
tation to environmental fluctuations [20,32]. In this
study, we demonstrated that H. bizzozeronii acquires re-
sistance to metronidazole at a mutation rate similar to
that described for phase-variable genes in Campylobacter
jejuni and other bacterial species [32]. In addition, we ob-
served an increased level of susceptibility to metronidazole
in a spontaneous mutant maintained in non-selective
conditions after approximately 15 passages, indicating
that the resistant phenotype is reversible. Based on
these data, it is tempting to speculate that metronida-
zole resistance in H. bizzozeronii is a phase-variable
phenotype due to the contingency nature of rdxA. How-
ever, several other unknown mechanisms could lead to
metronidazole resistance in H. bizzozeronii, overcoming
the stochastic variation. In addition, it is not clear how
frequently the reversion of the mutation (C9 to C8) oc-
curs. In fact, we recently detected that the larger fraction
of the H. bizzozeronii population colonizing the stomach
of a patient maintained the C9 allele in rdxA six months
after the end of the therapy [15]. Although it is clear that
disruption of the C-terminal cysteine conserved region of
rdxA decreases the ability of H. bizzozeronii to catalyze
the metronidazole nitroreduction, the effect of this muta-
tion on NAD(P)H-oxidase activity is unknown. Therefore,
it may be possible that the same mutation that provides
resistance to metronidazole does not alter the physio-
logical activity of rdxA, or paradoxically, induces an
increased fitness of the bacterium. This could lead to the
fixation of the mutation in the population, as observed in
the patient [15].
In conclusion, H. bizzozeronii, and potentially other
species of H. heilmannii s.l., easily acquired clinically
significant resistance to metronidazole due to the high
mutation rate of SSCR located in the 3′ region of rdxA.
Although we observed in vitro reversibility of the phe-
notype, there is evidence that the mutation can be
maintained in vivo even six months after the end of
therapy. Therefore, the contingency nature of rdxA
should be carefully considered when metronidazole is
used in the treatment of H. heilmannii-associated
gastritis in humans.
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